Volume 114, Issue 2 pp. 297-300
Article

Complications of Microdebrider-Assisted Powered Intracapsular Tonsillectomy and Adenoidectomy

Alexander Sorin MD

Alexander Sorin MD

New York Otolaryngology Institute, New York, New York, U.S.A.

Search for more papers by this author
John P. Bent MD

Corresponding Author

John P. Bent MD

New York Otolaryngology Institute, New York, New York, U.S.A.

John P. Bent, MD, New York Otolaryngology Institute, 186 East 76th Street, New York, NY 10021, U.S.A.Search for more papers by this author
Max M. April MD

Max M. April MD

New York Otolaryngology Institute, New York, New York, U.S.A.

Search for more papers by this author
Robert F. Ward MD

Robert F. Ward MD

New York Otolaryngology Institute, New York, New York, U.S.A.

Search for more papers by this author
First published: 14 May 2009
Citations: 75

Abstract

Objectives: To study complications of powered intracapsular tonsillectomy and adenoidectomy (PITA) in pediatric patients with obstructive sleep apnea (OSA).

Study Design: Retrospective chart review and long-term follow-up in office or by telephone interview.

Methods: We studied 278 patients who underwent PITA between September 2000 and October 2002. Outcome measures were postoperative bleeding, velopharyngeal insufficiency, need for hospital readmission, tonsil regrowth, and return of snoring or sleep apnea symptoms.

Results: All 278 children treated by PITA had immediate resolution of symptoms of OSA. Complications were noted in 11 patients (3.9%). Nine patients (3.2%) experienced tonsil regrowth with snoring, two of whom evolved to a return of OSA that was definitively managed by means of a complete tonsillectomy. Two patients (0.7%) had selflimited bleeding. None of the patients developed persistent velopharyngeal insufficiency or required hospital readmission.

Conclusions: Microdebriderassisted PITA is a safe and effective alternative for children otherwise treated with traditional tonsillectomy for symptoms of OSA due to adenotonsillar hypertrophy. This series suggests a 3.9% overall rate of complications, with the most common noted as tonsillar regrowth without recurrence of OSA. Prospective trials with longer follow-up may define higher complication rates.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.